Acute myeloid leukemia: 2019 update on risk‐stratification and management

  title={Acute myeloid leukemia: 2019 update on risk‐stratification and management},
  author={Elihu H Estey},
  journal={American Journal of Hematology},
  pages={1267267 - 1291}
  • E. Estey
  • Published 1 October 2018
  • Medicine
  • American Journal of Hematology
Outcome in patients with acute myeloid leukemia (AML) ranges from death within a few days of beginning treatment (treatment related mortality, TRM) to likely cure. The major reason patients are not cured is resistance to treatment, often manifested as relapse from remission, rather than, even in older patients, TRM, whose incidence is decreasing. Knowledge of the pre‐treatment mutation status of various genes has improved our ability to assign initial treatment and, of particular importance… 

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease

This narrative review discusses MRD evaluation as biomarker for tailored therapy in AML patients; current evidence on the use of MRD in clinical practice is reported; and the potential ability of MRd in the assessment of the efficacy of new molecules is commented on.

Acute myeloid leukemia: 2021 update on risk‐stratification and management

  • E. Estey
  • Medicine
    American journal of hematology
  • 2020
Results with the recently‐ approved drugs compared with their predecessors are reviewed and other potential options are described, discussing benefit/risk ratios underlying the decision to offer allogeneic transplant and the importance of measurable residual disease.

Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

In patients allografted for AML disease relapse continues to represent the commonest cause of transplant failure and the development of novel strategies with the potential to reduce disease recurrence represents a major unmet need.

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia

The current knowledge on non-APL AML MRD assessment and possible clinical consequences is reviewed, finding that there still do not have proof that early intervention in MRD-positive AML patients would improve outcomes, although this is very likely.

Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3 + 7?

For most treatment‐naïve patients, it is now evident that standard 3 + 7 represents undertreatment in that the addition of new compounds results in better quality of response and improved survival.

Is outcome of older people with acute myeloid leukemia improving with new therapeutic approaches and stem cell transplantation?

Appropriate selection among different options on the basis of clinical fitness and molecular findings at diagnosis as well as at relapse would result in improvement of therapeutic results, sparing unnecessary toxicity and optimizing health systems resources.

Current strategies for detection and approach to easurable residual disease in Acute Myeloid Leukemia.

Baseline cytogenetic/genetic features have been widely recognized to play a critical prognostic role in acute myeloid leukemia (AML) and have proven useful in designing riskadapted treatment

Targeting Amino Acids to Treat AML

Researchers have discovered that metabolic reprograming, an emerging hallmark, is closely related to the diagnosis, treatment and prognosis of AML patients, which also provide potential therapeutic target for drug discovery.

Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease

Novel combination treatments may provide useful bridging strategies, beyond potentially improving outcomes for patients who are not candidates for intensive approaches, and aim to prevent the occurrence of leukemic evolution.



Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

  • R. WalterM. Othus E. Estey
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Data suggest that age is primarily a surrogate for other covariates, which themselves add significantly to predictive accuracy, thus challenging the wisdom of using age as primary or sole basis for assignment of intensive, curative intent treatment in AML.

Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000

The objective of the current study was to analyze the results from second salvage therapies in patients with AML since 2000 with regard to response and survival.

How I treat refractory and early relapsed acute myeloid leukemia.

Novel therapies include tyrosine kinase inhibitors, small-molecule inhibitors, inhibitors of mutated isocitrate dehydrogenase (IDH) 1 and IDH2, antibody- based therapies, and cell-based therapies, likely to enter clinical practice rapidly as a bridge to transplant and/or in older, unfit patients who are not candidates for allogeneic HSCT.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents

This research retrospectively collected and analyzed data from 71 mutation-positive AML patients treated with hypomethylating agents between 2007 and 2016 in eight European centers and one American center to address the issue of whether an NPM1 mutation also confers a good prognosis to patients unfit for intensive chemotherapy who are treated with HypomethYLating agents.

Prognostic index for adult patients with acute myeloid leukemia in first relapse.

The prognostic index estimates the outcome of AML patients in first relapse using four commonly applied clinical parameters and might identify patients who are candidates for salvage and investigational therapy.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

An international panel to provide updated evidence- and expert opinion-based recommendations for diagnosis and management of acute myeloid leukemia in adults includes a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease.

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial.

It is concluded that MRD status after the second consolidation may be the best timing for treatment choice, and risk-directed risk stratification treatment may improve the outcome of t(8;21) AML in CR1.

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

Prognostic factors, including the mutational status of 18 genes assessed by next-generation sequencing (NGS), in 96 newly diagnosed AML patients who received the first line treatment with AZA are reported.

Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia.

Wait a short period of time for laboratory tests to characterize leukemias better and design adapted therapeutic strategies at diagnosis seems possible, and TDT had no impact on overall survival and response rate.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients.

The effect of time from AML diagnosis to treatment (TDT) on complete remission (CR) and overall survival (OS) and results did not change with inclusion of cytogenetic data or in risk group subsets.